Ambroxol and LTI-291 (chaperone molecules aimed to increase the level or activity of glucocerebrosidase) and venglustat (a glucosylceramide synthase inhibitor) are now tested in clinical studies for Parkinson’s disease [170]. This evidence concerns the gene UGCG and Parkinson disease.